We are live on ! Find out more
CCM

Camber Capital Management Portfolio holdings

AUM $1.07B
1-Year Est. Return 8.19%
This Fund
S&P 500
This Quarter Est. Return
-9.29%
1 Year Est. Return
-8.19%
3 Year Est. Return
+26.6%
5 Year Est. Return
+54.57%
10 Year Est. Return
+164.72%
AUM
$1.92B
AUM Growth
-$354M
Cap. Flow
-$189M
Cap. Flow %
-9.84%
Top 10 Hldgs %
55.64%
Holding
47
New
10
Increased
8
Reduced
6
Closed
11

Top Buys

Rank Stock Value
1
AGN
Allergan plc
AGN
+$112M
2
MYGN icon
Myriad Genetics
MYGN
+$73.5M
3
VRTX icon
Vertex Pharmaceuticals
VRTX
+$61M
4
BIIB icon
Biogen
BIIB
+$51.9M
5
ABT icon
Abbott
ABT
+$39.7M

Top Sells

Rank Stock Value
1
MDCO
Medicines Co
MDCO
+$75.5M
2
CYH icon
Community Health Systems
CYH
+$57.7M
3
THC icon
Tenet Healthcare
THC
+$56.6M
4
BHC icon
Bausch Health
BHC
+$31.2M
5
PTCT icon
PTC Therapeutics
PTCT
+$28M

Sector Composition

Rank Sector Weight
1 Healthcare 74.66%
2 Industrials 1.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TEVA icon
1
Teva Pharmaceuticals
TEVA
$40.4B
$171M 8.92%
4,724,450
+724,450
+18% +$28.9M
VTRS icon
2
Viatris
VTRS
$20.8B
$158M 8.24%
4,145,889
+272,889
+7% +$10.1M
SYK icon
3
PUT
Stryker
SYK
$135B
$120M 6.24%
+1,000,000
New +$115M
AGN
4
DELISTED
Allergan plc
AGN
$114M 5.94%
+543,000
New +$112M
GILD icon
5
Gilead Sciences
GILD
$165B
$107M 5.59%
1,500,000
+300,000
+25% +$22.3M
PRGO icon
6
Perrigo
PRGO
$1.44B
$101M 5.24%
1,208,200
-5,400
-0.4% -$468K
SEM
7
DELISTED
Select Medical
SEM
$79.8M 4.16%
11,182,400
– –
NKTR icon
8
Nektar Therapeutics
NKTR
$2.39B
$73.6M 3.83%
400,000
+186,667
+88% +$38M
GHDX
9
DELISTED
Genomic Health, Inc.
GHDX
$72.2M 3.76%
2,458,100
– –
GILD icon
10
CALL
Gilead Sciences
GILD
$165B
$71.6M 3.73%
1,000,000
– –
BKD icon
11
Brookdale Senior Living
BKD
$3.55B
$68.3M 3.56%
5,500,000
+1,500,000
+38% +$20.1M
MYGN icon
12
Myriad Genetics
MYGN
$476M
$67.7M 3.52%
+4,060,000
New +$73.5M
ENDP
13
DELISTED
Endo International plc
ENDP
$64.3M 3.35%
3,902,000
-338,000
-8% -$5.95M
CSII
14
DELISTED
Cardiovascular Systems, Inc.
CSII
$60.5M 3.15%
2,500,000
-500,000
-17% -$12.3M
ALKS icon
15
Alkermes
ALKS
$8.11B
$55.6M 2.89%
1,000,000
+62,700
+7% +$3.35M
VRTX icon
16
Vertex Pharmaceuticals
VRTX
$123B
$55.3M 2.88%
+750,000
New +$61M
OFIX icon
17
Orthofix Medical
OFIX
$492M
$54.3M 2.83%
1,500,000
– –
LIVN icon
18
LivaNova
LIVN
$4.47B
$54M 2.81%
1,200,000
+200,000
+20% +$9.83M
BIIB icon
19
Biogen
BIIB
$30.9B
$49.6M 2.58%
+175,000
New +$51.9M
UAM
20
DELISTED
Universal American Corp
UAM
$48.5M 2.53%
4,875,000
-1,000,000
-17% -$8.78M
ABT icon
21
Abbott
ABT
$187B
$38.4M 2%
+1,000,000
New +$39.7M
CNMD icon
22
CONMED
CNMD
$1.3B
$33.1M 1.73%
750,000
– –
ATHN
23
DELISTED
Athenahealth, Inc.
ATHN
$31.6M 1.64%
+300,000
New +$32.2M
AMAG
24
DELISTED
AMAG Pharmaceuticals
AMAG
$21.3M 1.11%
611,390
– –
ELGX
25
DELISTED
Endologix Inc
ELGX
$20.8M 1.08%
363,500
+263,500
+264% +$24.1M
1
2

Similar funds

PP
PrairieView Partners St. Paul, Minnesota $1.03B AUM 11.4% 1-Year Est. Return
SAF
Smith Anglin Financial Dallas, Texas $1.1B AUM 14.08% 1-Year Est. Return
NRD
Nebula Research & Development New York $1.17B AUM 15.19% 1-Year Est. Return
FC
Forte Capital Rochester, New York $930M AUM 24.11% 1-Year Est. Return
GIM
Grassi Investment Management Santa Clara, California $1.26B AUM 23.4% 1-Year Est. Return
SC
Savoie Capital Chicago, Illinois $805M AUM 19.48% 1-Year Est. Return
BWA
Bordeaux Wealth Advisors Menlo Park, California $781M AUM 26.55% 1-Year Est. Return
CCP
Camelot Capital Partners Laguna Beach, California $686M AUM 163.55% 1-Year Est. Return

Camber Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, Camber Capital Management held 47 positions worth $1.92B, down 16% from $2.27B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Camber Capital Management withdrew a net $189M in Q4 2016, closing 11 positions and reducing 6 holdings. Its most notable exit was Medicines Co, an estimated $75.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 75% of assets, up from 58% a quarter earlier, followed by Industrials.

Against the trend, Camber Capital Management opened a new position in Allergan plc worth $114M.

  • Camber Capital Management's largest Q4 2016 buy was Allergan plc: 543,000 shares worth $114M.
  • Camber Capital Management added most to Nektar Therapeutics in Q4 2016, an estimated $38M increase.
  • Camber Capital Management's biggest Q4 2016 reduction was Cardiovascular Systems, Inc., cutting an estimated $12.3M.
  • Camber Capital Management fully exited Medicines Co in Q4 2016, selling an estimated $75.5M.
  • Camber Capital Management's ten largest holdings make up 56% of its $1.92B portfolio in Q4 2016.
  • Camber Capital Management opened 10 new positions and closed 11 in Q4 2016.
  • Camber Capital Management's portfolio value fell 16% quarter-over-quarter to $1.92B.

Based on Camber Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.